New Market Research Report: Mexico Pharmaceuticals & Healthcare Report Q2 2015

Increased trade activity will promote growth in Mexico's pharmaceutical a nd healthcare markets in 2015. In particular, generic medicine will continue to grow over the forecast period, accounting for a larger percentage of total pharmaceutical spending. Indeed, the country will continue to see positive changes as government regulations improve industry appeal to foreign drugmakers.

Headline Expenditure Projections

* Pharmaceuticals: MXN185bn (USD14bn) in 2014 to MXN192bn (USD15bn) in 2015; +7.2% in local currency terms and +5.8% in US dollar terms. Forecast increased from Q115 due to revised historical data.
* Healthcare: MXN1,124bn (USD85bn) in 2014 to MXN1,1214bn (USD91bn) in 2015; +8.0% in local currency terms and +6.6% in US dollar terms. Forecast increased from Q115 due to revised historical data.

Risk/Reward Index

Mexico scores 60.6 in BMI's Pharmaceutical and Healthcare Risk/Reward Index (RRI), making it the fifth-most attractive pharmaceutical market in the region.

Full Report Details at
- http://www.fastmr.com/prod/951953_mexico_pharmaceuticals_healthcare_report_q2_2015.aspx?afid=301

Key Trends And Developments

January 2015

* Mexico's National Strategy for Prevention and Control of Overweight, Obesity and Diabetes published results that in 2014, their program was successful in decreasing mortality rates of diabetes by 1% and cardiovascular disease by 2.6%.
* COFEPRIS (Federal Commission for the Protection against Sanitary Risk) reported having removed more than 119,000 pharmaceutical advertisements throughout 2014. The ads, which were considered to be irregular, accrued more than MXN70mn (USD5mn) in fines.

December 2014

* Mexico became the largest exporter of pharmaceutical products in Latin America with its pharmaceutical industry accounting for 1.2% of its gross domestic product.
* The Mexican government made the largest purchase of pharmaceuticals in the history of the public sector, spending MXN51bn (USD3.5bn) on imported medicines for 2015. The figure is MXN8bn (549mn) more than the previous year.

BMI Economic View: Mexico's current account deficit...

The Mexico Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Mexico Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Mexico pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Mexico, to test other views - a key input for successful budgeting and strategic business planning in the Mexican pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Nigeria Pharmaceuticals & Healthcare Report Q2 2015
- Thailand Pharmaceuticals & Healthcare Report Q2 2015
- Croatia Pharmaceuticals & Healthcare Report Q2 2015
- Kenya Pharmaceuticals & Healthcare Report Q2 2015
- Puerto Rico Pharmaceuticals & Healthcare Report Q2 2015